Kriya Therapeutics

Kriya Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing medicine through the development of gene therapies. Founded in 2019, Kriya aims to address diseases affecting millions of people globally by making gene therapies accessible not just for rare conditions but for prevalent ones as well. The company operates with a fully integrated model, encompassing advanced manufacturing technologies, computational tools, and robust development capabilities. This integrated approach is designed to overcome traditional challenges in the gene therapy field, such as manufacturing complexities, vector design limitations, and high costs, thereby improving speed to market and reducing the cost per dose.

Kriya's core operations are strategically located in Palo Alto, California, and Research Triangle Park, North Carolina, leveraging the innovation ecosystems of both Silicon Valley and a leading biotech hub. The company is advancing a broad and diversified pipeline of gene therapies across several key therapeutic areas, including ophthalmology, neurology, and metabolic diseases. Within these areas, Kriya focuses on conditions with significant unmet medical needs, validated biological targets, and well-defined clinical endpoints to facilitate rapid proof-of-concept and accelerated translational development. The company has successfully raised over $600 million in committed capital from leading healthcare and technology investors, underscoring strong confidence in its mission and approach. Kriya's leadership team comprises experienced drug developers and pioneers in genetic medicine, clinical research, and complex biologics, all committed to building a leading global gene therapy biopharmaceutical company with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease.